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Abstract 26
Insulin resistance is central to the development of type 2 diabetes and related metabolic 27 disorders. As skeletal muscle is responsible for the majority of whole body insulin-stimulated 28 glucose uptake, regulation of glucose metabolism in this tissue is of particular importance. 29
While Rho GTPases and many of their affecters influence skeletal muscle metabolism, there 30 is a paucity of information on the protein kinase N (PKN) family of serine/threonine protein 31 kinases. We investigated the impact of PKN2 on insulin signaling and glucose metabolism in 32 primary human skeletal muscle cells in vitro and mouse tibialis anterior muscle in vivo. As skeletal muscle is the predominant site of insulin-stimulated glucose uptake, skeletal 49 muscle insulin resistance is a major contributing factor to defective blood glucose disposal in 50 type 2 diabetes (5, 6). The physiological role of novel and previously identified candidate 51 genes/proteins that regulate inter-and intra-cellular signaling pathways controlling cellular 52 and whole body glucose and lipid homeostasis is an active area of current research. Through 53 the discovery of key regulatory proteins in glucose and energy homeostasis, new diabetes 54 prevention and treatment targets may be identified. 55
The Rho family of guanosine triphosphatases (GTPases), comprised of Rho, Rac and 56 CDC42, are essential regulators of diverse biological functions including glucose 57 metabolism. In particular, Rac1 is essential for both insulin-dependent and independent 58 glucose uptake in skeletal muscle (31, 32) . Rho GTPases utilize protein kinases to elicit many 59 of their downstream effects. Among the Ser/Thr kinases that function as Rho GTPase effector 60 molecules are Rho-(ROCK1/2), p21-activated (PAK1-PAK6), and protein kinase N (PKN1-61 PKN3) kinases (38) . While members of the ROCK and PAK family have well-established 62 roles in glucose metabolism and insulin signaling, little is known regarding the function of 63 PKNs in skeletal muscle metabolic regulation (12, 33, 34) . 64
PKNs are members of the atypical protein kinase C subfamily known for regulating actin 65 cytoskeletal rearrangement and cell migration. While the three mammalian PKN family 66 members share a large degree of homology in their C-terminal catalytic domain, variation in 67 their regulatory domain results in selectivity to upstream signals (17, 21) . Both PKN1 and 68 PKN2 respond to Rho and Rac, but these isoforms display differential responsiveness to 69 lipids and binding partner proteins (10, 11, 13, 21, 24, 26) . Importantly, PKN2 represents the 70 majority of Rho associated autophosphorylation activity in all tissues tested (36). A high 71 degree of isoform selectivity was confirmed by the finding that mice lacking PKN1, PKN3 or 72 both are without overt phenotype, while loss of PKN2 is embryonically lethal (25) . 73
In addition to Rho GTPases, phosphoinositide-dependent kinase-1 (PDK1), a key kinase 74 in the insulin signaling cascade, stimulates PKNs by phosphorylation of the activation loop 75 (9). In adipocytes, insulin stimulates PKN activity and PKN1 transmits the insulin signal to 76 the actin cytoskeleton (9, 30). Conversely, PKNs may inhibit insulin signaling by directly 77 interacting with PDK1 and Akt (8, 15, 35 
RESULTS

174
Gene silencing of PKN2 does not alter myotube differentiation. 175
To assess the impact of PKN2 on skeletal muscle metabolism, primary human skeletal 176 muscle cells were transfected with PKN2 siRNA on days 4 and 6 after the initiation of 177 differentiation. This treatment achieved a robust knockdown of PKN2 mRNA and protein 178 (Fig 1A and 1B) . As PKN2 regulates myotube differentiation in C2C12 cells (18), we sought 179 to ensure that PKN2 knockdown did not alter the differentiation status of the human 180 myotubes used here. Visual appearance of cultures, as well as mRNA expression and protein 181 abundance of myogenic (desmin) and proliferative markers (PAX7) were unchanged (Fig 1A, 182 1B and 1C) . Myotube protein to DNA ratio was unchanged by siRNA treatment (Scr: 183 0.84±0.07 mg protein/mg DNA; PKN2: 0.86±0.05 mg protein/mg DNA; n=5). 184
185
Role of PKN2 in glucose metabolism and insulin signaling. 186
Having established that PKN2 knockdown does not alter the differentiation status of HSMCs, 187 we utilized radioactive tracer based methods to assess glucose metabolism. PKN2 188 knockdown decreased insulin-stimulated glucose uptake and incorporation into glycogen 189 without altering basal glucose metabolism (Fig 1D and 1E) . Similarly, insulin-stimulated 190 glucose oxidation was diminished in cells depleted of PKN2 (Fig 1F) . 191 PKN2 has been reported to be phosphorylated by PDK1 (9). Given that PKN2 192 knockdown diminished insulin-responsiveness of glucose metabolism, we sought to 193 determine if PKN2 constitutes a branch of, or otherwise influences, insulin signaling. 194
Western blot analysis revealed that insulin treatment of either HSMC (Fig 2A) or mouse 195 quadriceps muscle (Fig 2B) did not alter phosphorylation of the activation loop in either 196 PKN2 or PKN1. PKN2 knockdown did not alter the phosphorylation of Akt or GSK3α/β (Fig  197   2A ). However, PKN2 knockdown increased phosphorylation of TBC1D4 under both basal 198 and insulin-stimulated conditions in HSMC (Fig 2A, 2C) . Thus, the activation loop of PKN2 199 does not appear to be phosphorylated in response to insulin. 
PKN2 gene silencing increases lipid metabolism and genes involved in lipid handling. 215
To determine if PKN2 knockdown influences lipid metabolism, fatty acid oxidation and lipid 216 fate was assessed in HSMC incubated in the absence or presence of the AMPK activator 217 AICAR. PKN2 knockdown increased both basal and AICAR-stimulated fatty acid oxidation 218 (Fig 4A) . Similar to AICAR treatment, PKN2 knockdown decreased palmitate incorporation 219 into 1,3-diacylglycerol and the origin, which contains polar lipids (Fig 4B) . Interestingly, 220 PKN2 markedly increased incorporation of palmitate into triglycerides (Fig 4B) . To gain 221 insight into mechanisms by which PKN2 alters lipid metabolism, we performed qPCR 222 analysis of genes involved in lipid handling and synthesis. PKN2 knockdown increased 223 expression of the transcriptional co-activator PGC-1α and several of its target genes (CPT1β, 224 PDK4, FABP3) (Fig 4C) . PKN2 silencing also increased expression of genes involved in 225 fatty acid synthesis (SCD1, FASN, SREBP1c) and, unexpectedly, decreased the expression 226 of genes involved in triglyceride synthesis (DGAT1 and GPAT1) (Fig 4D) . 227 228 PKN2 gene silencing decreased mTOR signaling and protein synthesis. 229
As PKN2 knockdown led to increased AMPK signaling, we determined whether downstream 230 targets involved in protein metabolism might also be altered. Consistent with AMPK 231 activation, PKN2 knockdown decreased both basal and insulin-stimulated phosphorylation of 232 mTOR and S6 ribosomal protein (Fig 5A-C) . To determine whether these changes were 233 associated with alterations in protein metabolism, we performed a protein synthesis assay. 234 PKN2 knockdown decreased incorporation of phenylalanine into protein (Fig 5D) . Consistent 235 with AMPK activation, PKN2 knockdown decreased mTOR signaling and protein synthesis. 236 237 PKN2 knockdown in mature skeletal muscle. 238
To assess the impact of PKN2 gene silencing in mature skeletal muscle in vivo, contralateral 239 tibialis anterior muscles were electroporated with shRNA targeting PKN2 or a scrambled 240 control sequence. PKN2 shRNA produced a modest decrease in both PKN2 mRNA 241 expression (77±11% of control leg) and protein abundance (Fig 6A, 6B) . To determine 242 whether PKN2 gene silencing affects glucose uptake in adult skeletal muscle in vivo, we 243 performed a modified oral glucose tolerance test utilizing radiolabeled 2-deoxyglucose. 244 PKN2 depletion reduced glucose uptake in tibialis anterior muscle (Fig 6C) . Similarly, PKN2 245 silencing was associated with a trend (p=0.07) for decreased glycogen content in skeletal 246 muscle (Fig 6D) . We next determined whether PKN2 silencing activates AMPK signaling, by 247 assessing phosphorylation of AMPK and its substrate ACC in adult skeletal muscle. Similar 248 to our in vitro results, PKN2 silencing was associated with an increase in the phosphorylation 249 of AMPK (Fig 6A, 6E ) and its substrate ACC, although ACC phosphorylation did not reach 250 statistical significance (Fig 6A, 6F) . Thus, PKN2 knockdown in vivo inhibits glucose uptake 251 during a glucose challenge and activates AMPK signaling in mature skeletal muscle. Although we could not detect alterations in PKN2 phosphorylation in response to insulin, we 275 cannot exclude the possibility that insulin treatment alters PKN2 activity or localization (30). 276
Aside from a potential role within the insulin signaling cascade, PKN2 has been shown to 277 influence Akt signaling both by directly binding to PDK1 and indirectly influencing its 278 activity (8, 15, 35 
